Infectious Disease
Helicobacter Pylori Infection
0
Pipeline Programs↗
18
Active Trials↗
5
Companies Involved↗
Helicobacter Pylori Infection is an early-stage landscape with 0 programs across 5 companies. The most active players are Johnson & Johnson, Takeda, Livzon Pharmaceutical Group Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
92
clinical trials
Completed41 · 45%
Unknown status32 · 35%
Recruiting9 · 10%
Not yet recruiting6 · 7%
Enrolling by invitation2 · 2%
Withdrawn1 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
92 trials
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
Recruiting·—·Phase 3·NCT06734260·477 enrolled
The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection
Not yet recruiting·—·Phase 3·NCT06964334·70 enrolled
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
Not yet recruiting·—·N/A·NCT06731023·30 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)